BeStock  
Stocks › Biotechnology › ZYME

Zymeworks ZYME

US equityMarket cap rank #2745Biotechnology
$26.14 −$0.72 (-2.68%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $26.14 0.00%
Open$26.30
Prev close$26.86
Day range$26.09 – $27.57
Volume738.8K
Market cap$1.81B
P/E (TTM)49.3
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership101.1%+2.70 pts vs. prior quarter
Institutions holding253-5 vs. prior quarter
Insider trades (recent)31 buys / 4 sellsNet buying
Short interest8.39% of floatDays to cover 4.3 · as of 30 Oct 2026
Short-sale volume share28.9%5-day average of daily volume

Short-sale volume as % of daily volume

0%14%28%42%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$10.92M (6 inflow days, 14 outflow days).

Net flow by order size, last 20 sessions

−$4.8MSuper−$6.1MBig−$10.7MMid−$6.2MSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 60.9% of shares outstanding.

Largest holders

  • EcoR1 Capital, LLC33.28%
  • Rubric Capital Management LP10.14%
  • BlackRock6.10%
  • Perceptive Advisors LLC6.06%
  • BVF Partners L.P.5.29%
  • Morgan Stanley4.69%
  • BNPP Asset Management Holding2.36%
  • Vanguard Capital Management, LLC2.26%

By investor type

  • Hedge Fund53.85%
  • Mutual Fund31.87%
  • VC/PE Fund7.70%
  • Public Company6.43%
  • Individual/Insider1.38%
  • Private Company0.49%
  • Government Pension Fund0.41%
  • Bank/Investment Bank0.17%

Reported short interest has risen from 6.40% to 8.39% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Morgan Stanley Public Company 2026/Q3 +1,005,655 4.7%
Fisher Investments Mutual Fund 2026/Q3 +537,837 0.9%
Assenagon Asset Management S.A. Mutual Fund 2026/Q3 +256,042 2.2%
Franklin Resources Mutual Fund 2026/Q3 +93,047 0.2%
Invesco Capital Management LLC Mutual Fund 2026/Q3 +59,666 0.2%
Federated Hermes, Inc. Mutual Fund 2026/Q3 +58,984 0.4%
Russell Investment Management, LLC Mutual Fund 2026/Q3 +50,127 0.1%
Macquarie Investment Management Business Trust Mutual Fund 2026/Q3 +868,354 1.3%
Perceptive Advisors LLC VC/PE Fund 2026/Q3 +672,875 6.1%
Delaware Management Company Mutual Fund 2026/Q3 +600,846 0.9%
Assenagon Asset Management S.A. Mutual Fund 2026/Q3 +524,041 1.8%
First Trust Advisors L.P. Mutual Fund 2026/Q3 +340,363 0.5%
Pictet Asset Management Limited Mutual Fund 2026/Q3 +298,931 0.4%
Prosight Management, LP Hedge Fund 2026/Q3 +135,385 1.0%
Scotia Wealth Management Bank/Investment Bank 2026/Q3 +118,100 0.2%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
8 Oct 2026 Adam Schayowitz Executive VP and Head of Research & Development Derivative Exercise and Sale -13,832 $25.85 23,205
8 Oct 2026 Adam Schayowitz Executive VP and Head of Research & Development Derivative Exercise and Retained +23,205 – 23,205
5 Jul 2026 Mark Hollywood Chief Operating Officer Other Acquisition +939 $22.22 133,852
12 May 2026 Paul Schneider Executive Vice President Other Derivative Acquisition +119,000 – 119,000
12 May 2026 Paul Schneider Executive Vice President Other Derivative Acquisition +178,000 $24.57 178,000
12 May 2026 Paul Schneider Executive Vice President Initial Statement of Beneficial +0 – –
8 Apr 2026 Adam Schayowitz Executive VP and Head of Research & Development Other Derivative Acquisition +47,000 – 47,000
8 Apr 2026 Adam Schayowitz Executive VP and Head of Research & Development Other Derivative Acquisition +70,000 $27.35 70,000
8 Apr 2026 Adam Schayowitz Executive VP and Head of Research & Development Other Derivative Acquisition +76,000 – 76,000
8 Apr 2026 Adam Schayowitz Executive VP and Head of Research & Development Initial Statement of Beneficial +0 – 167,000
8 Apr 2026 Scott Platshon Executive VP & Chief Business Officer Other Derivative Acquisition +47,000 – 47,000
8 Apr 2026 Scott Platshon Executive VP & Chief Business Officer Other Derivative Acquisition +70,000 $27.35 70,000
8 Apr 2026 Scott Platshon Executive VP & Chief Business Officer Other Derivative Acquisition +76,000 – 76,000
8 Apr 2026 Scott Platshon Executive VP & Chief Business Officer Initial Statement of Beneficial +0 – 167,000
5 Apr 2026 Kristin Stafford Chief Financial Officer Other Derivative Acquisition +169,000 – 50,000
5 Apr 2026 Kristin Stafford Chief Financial Officer Other Derivative Acquisition +178,000 $25.84 178,000
31 Mar 2026 Kristin Stafford Chief Financial Officer Initial Statement of Beneficial +0 – –
31 Jan 2026 Sabeen Mekan Senior VP & Chief Medical Officer Initial Statement of Beneficial +0 – 221,000
11 Jan 2026 Kenneth Galbraith Chairperson & CEO Derivative Exercise and Sale -30,424 $22.67 226,842
11 Jan 2026 Kenneth Galbraith Chairperson & CEO Other Derivative Acquisition +144,000 – 144,000

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 5,914,601 8.4% 4.3
15 Oct 2026 5,577,540 7.8% 4.4
30 Sep 2026 5,291,136 7.4% 5.6
15 Sep 2026 4,939,072 7.0% 8.0
31 Aug 2026 4,724,831 6.7% 5.7
14 Aug 2026 4,538,353 6.4% 8.5

Discussion

No comments yet — be the first to weigh in on ZYME.

Sign in to join the discussion.

Scroll to Top